In the NAFLD group, miR-466i-3p- and miR-669c-3p-related AMPK downregulation was accompanied by a significant increase in SREBP1 and FASN levels, which suggested that the activation of the AMPK signaling pathway was reduced. Here, SREBF1 is linked to metabolic dysfunction-associated steatotic liver disease.